The CHOICE trial: Adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohns disease who failed prior infliximab therapy

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 10, 2010, Pages 1228-1239

  Lichtiger, S ^a   Binion, D G ^b   Wolf, D C ^c   Present, D H ^a   Bensimon, A G ^d   Wu, E ^d   Yu, A P ^d   Cardoso, A T ^e   Chao, J ^e   Mulani, P M ^e   Lomax, K G ^e   Kent, J D ^e  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Atlanta Gastroenterology Associates   (United States)

^d ANALYSIS GROUP   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABSCESS; ADULT; AGED; ALLERGIC REACTION; ANUS FISTULA; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEHYDRATION; DEMYELINATING DISEASE; DIGESTIVE SYSTEM FISTULA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HEALING; HUMAN; ILEAL STENOSIS; INFECTION; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; OPEN STUDY; OPPORTUNISTIC INFECTION; PERIRECTAL ABSCESS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SKIN CANCER; SKIN FISTULA; SMALL INTESTINE OBSTRUCTION; STENOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS;

ABSCESS; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; EFFICIENCY; FEMALE; FISTULA; HUMANS; MALE; QUALITY OF LIFE; TREATMENT OUTCOME; WORK; WOUND HEALING;

EID: 78249282645     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04466.x     Document Type: Article

References (41)

1. Loftus EV Jr, Schoedenfeld P, Sandborn WJ,. The epidemiology and natural history of Crohns disease in population-based patient cohorts from North America: a systemic review. Ailment Pharmacol Ther 2002; 16: 51-60.
2. Management of Crohns disease in adults, Lichtenstein GR, Hanauer SB, Sandborn WJ,. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2009; 104: 465-83.
3. Travis SPL, Stange EF, Lãmann M, et al. European evidence based consensus on the diagnosis and management of Crohns disease: current management. Gut 2006; 55 (Suppl. 1): i16-35.
4. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohns disease: definitions and diagnosis. Gut 2006; 55 (Suppl. 1): 1-15.
5. Cohen RD,. The quality of life in patients with Crohns disease. Ailment Pharmacol Ther 2002; 9: 1603-9.
6. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohns disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001; 96: 2915-20.
7. Feagan BG, Bala M, Yan S, Olson A, Hanauer S,. Unemployment and disability in patients with moderately to severely active Crohns disease. J Clin Gastroenterol 2005; 39: 390-5.
8. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohns disease. Am J Gastroenterol 2008; 103: 154-61.
9. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL,. The cost of hospitalization in Crohns disease. Am J Gastroenterol 2000; 95: 524-30.
10. Longobardi T, Jacobs P, Bernstein CN,. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98: 1064-72.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med 2003; 348: 601-8.
12. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
13. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
14. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
16. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC I trial. Gastroenterology 2006; 130: 323-33.
17. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
18. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007; 146: 829-38.
19. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
20. Irvine EJ, Zhou Q, Thompson AK,. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohns Relapse Prevention Trial. Am J Gastroenterol 1996; 91: 1571-8.
21. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
22. Reilly MC, Brown MC, Brahant Y, Gerlier L, Tan SC, Sandborn WJ,. Defining the minimally important difference for WPAI: CD Scores: What is a relevant impact on work productivity in active Crohns disease? Gut 2007; 56 (Suppl. 3): A159.
23. Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from trials of six immune mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
24. Colombel J-F, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohns disease. Inflamm Bowel Dis 2009; 15: 1308-19.
25. Rutgeerts P, DHaens GR, Van Assche GA, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohns disease-first results of the EXTEND trial. Gastroenterology 2009; 5 (Suppl. 1): A-116.
26. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohns disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
27. Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM,. Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohns disease. Manag Care Interface 2008; 21: 20-3.
28. Loftus EV, Feagan BG, Colombel J-F, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohns disease: patient-reported outcomes of the CHARM trial [published correction appears in Am J Gastroenterol 2009; 104: 1894]. Am J Gastroenterol 2008; 103: 3132-41.
29. HUMIRA® [Prescribing Information]. North Chicago, IL: Abbott Laboratories, 2010.
30. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohns disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 787-96.
31. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT,. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naãve patients. Aliment Pharmacol Ther 2009; 29: 273-8.
32. Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack PF,. Adalimumab effectiveness in TNF-antagonist-naãve Patients and in infliximab nonresponders with Crohns disease: results from the CARE study. Am J Gastroenterol 2008; 103 (Suppl. 1): S418.
33. Van Assche G, Vermeire S, Rutgeerts P,. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008; 10: 591-6.
34. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
35. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohns disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2010 [Epub ahead of print].
36. Loftus EV Jr, Pan X, Zurawski P, et al. Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohns disease in the United States. Gastroenterology 2009; 5 (Suppl. 1): A-175-6.
37. Wu EQ, Mulani PM, Yu A, Tang J, Pollack PF,. Loss of treatment response to infliximab maintenance therapy in Crohns disease: a payor perspective. Value Health 2008; 11: 820-9.
38. Regueiro M, Siemanowski B, Kip KE, Plevy S,. Infliximab dose intensification in Crohns disease. Inflamm Bowel Dis 2007; 13: 1093-9.
39. Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA,. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohns fistulas. Aliment Pharmacol Ther 2009; 30: 757-66.
40. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohns disease. Gut 2009; 58: 940-8.
41. Reilly MC, Gerlier L, Brabant Y, Brown M,. Validity, reliability, and responsiveness of the Work Productivity and Activity Impairment Questionnaire in Crohns disease. Clin Ther 2008; 30: 393-404.